Tanaka T et al. – In intraarterial administration of 5–FU at a dose of 1000 mg/m2 combined with full–dose systemic gemcitabine for unresectable pancreatic cancer, the toxicity rate was acceptable, and response rate and survival time improved over those for treatment with gemcitabine alone.
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor